MD FACR - Hyperfine Vice Affairs
| HYPR Stock | USD 1.01 0.03 3.06% |
Executive
MD FACR is Vice Affairs of Hyperfine
| Address | 351 New Whitfield Street, Guilford, CT, United States, 06437 |
| Phone | 866 796 6767 |
| Web | https://hyperfine.io |
Hyperfine Management Efficiency
The company has return on total asset (ROA) of (0.2965) % which means that it has lost $0.2965 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4874) %, meaning that it created substantial loss on money invested by shareholders. Hyperfine's management efficiency ratios could be used to measure how well Hyperfine manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Tangible Assets is likely to drop to -0.49. In addition to that, Return On Capital Employed is likely to drop to -0.59. At this time, Hyperfine's Total Assets are relatively stable compared to the past year. As of 11/29/2024, Net Tangible Assets is likely to grow to about 149.4 M, while Non Currrent Assets Other are likely to drop slightly above 1.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MBA MD | Inogen Inc | 51 | |
| Chris Williamson | Iradimed Co | N/A | |
| Trui Hebbelinck | LivaNova PLC | 52 | |
| Matthew III | LivaNova PLC | N/A | |
| Mark Namaroff | Anika Therapeutics | 61 | |
| Jrme Erath | Pulmonx Corp | N/A | |
| Sarah Huber | Pulmonx Corp | N/A | |
| Lucas Vitale | Orthofix Medical | 47 | |
| Frank Vizesi | Orthofix Medical | N/A | |
| Matthew CPA | Apyx Medical | 55 | |
| Gordon Weber | SurModics | 61 | |
| Krishna Jhaveri | Inogen Inc | N/A | |
| David JD | Pulmonx Corp | 63 | |
| Randy Waddell | Iradimed Co | N/A | |
| Jill Mason | Orthofix Medical | N/A | |
| Ben Joseph | Anika Therapeutics | N/A | |
| Michael CPA | Anika Therapeutics | 50 | |
| Marcee Maroney | Pulmonx Corp | 54 | |
| Michael Levitz | Anika Therapeutics | 50 | |
| David Lehman | Pulmonx Corp | 63 | |
| James Chase | Anika Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 |
Hyperfine Leadership Team
Elected by the shareholders, the Hyperfine's board of directors comprises two types of representatives: Hyperfine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hyperfine. The board's role is to monitor Hyperfine's management team and ensure that shareholders' interests are well served. Hyperfine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hyperfine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott White, Chief Officer | ||
| Neela Paykel, Gen Officer | ||
| Alok Gupta, Chief Officer | ||
| Thomas Teisseyre, Chief Officer | ||
| Dave Castiglioni, Chief Officer | ||
| Maria Sainz, President CEO | ||
| Brett Hale, CFO, Officer | ||
| Edmond MD, Chief Officer | ||
| Mark Hughes, VP Operations | ||
| Jonathan Rothberg, Founder Chairman | ||
| Khan MD, Chief Officer | ||
| Kyla JD, Chief Officer | ||
| MD FACR, Vice Affairs | ||
| Tom Teisseyre, Chief Officer |
Hyperfine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hyperfine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (2.99) % | ||||
| Current Valuation | 25.93 M | ||||
| Shares Outstanding | 57.89 M | ||||
| Shares Owned By Insiders | 9.00 % | ||||
| Shares Owned By Institutions | 24.35 % | ||||
| Number Of Shares Shorted | 1.5 M | ||||
| Price To Book | 1.23 X | ||||
| Price To Sales | 5.99 X |
Pair Trading with Hyperfine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Hyperfine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hyperfine will appreciate offsetting losses from the drop in the long position's value.Moving against Hyperfine Stock
| 0.54 | MD | Mednax Inc | PairCorr |
| 0.52 | LH | Laboratory | PairCorr |
| 0.51 | DOCS | Doximity | PairCorr |
| 0.51 | ELMD | Electromed | PairCorr |
| 0.41 | OM | Outset Medical | PairCorr |
The ability to find closely correlated positions to Hyperfine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Hyperfine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Hyperfine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Hyperfine to buy it.
The correlation of Hyperfine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Hyperfine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Hyperfine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Hyperfine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Hyperfine Stock Analysis
When running Hyperfine's price analysis, check to measure Hyperfine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hyperfine is operating at the current time. Most of Hyperfine's value examination focuses on studying past and present price action to predict the probability of Hyperfine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hyperfine's price. Additionally, you may evaluate how the addition of Hyperfine to your portfolios can decrease your overall portfolio volatility.